Gastrointestinal stromal tumor with rhabdomyosarcoma differentiation after imatinib targeted therapy:A case report and literature review
Gastrointestinal stromal tumor(GIST)is the most common mesenchymal tumor of the digestive tract.With the application of imatinib,the efficacy of treatment for advanced GIST has significantly improved.Although most patients benefit from imatinib therapy,some patients develop secondary resistance.In this particular case,a GIST patient developed resistance and tumor progression after 15 months of imatinib treatment.Microscopic examination showed significant polymorphism in some tumor cells and immunohistochemistry indicated rhabdomyoblastic differentiation.No secondary mutations in the c-Kit and PDGFRA genes were found in the progressive lesions.Due to the rarity of rhabdomyosarcoma dedifferentiation in GIST,this case report will aid in the diagnosis of GIST following imatinib treatment,helping to avoid misdiagnosis and missed diagnosis.
国家科技期刊平台
NSTL
万方数据
